Oprozomib

Generic Name: Oprozomib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₂N_₄O_₇S

CAS Number: 935888-69-0

Unique Ingredient Identifier: MZ37792Y8J

Background: Oprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS) Malignancies.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Multiple Myeloma Market Will Expand With Launch of New Treatments

The multiple myeloma (MM) market is expected to grow significantly, driven by monoclonal antibodies elotuzumab and daratumumab. MM, a blood cancer, affects bone marrow and blood cell production. Treatments include chemotherapy, biologic therapy, and stem-cell transplant. New drugs like elotuzumab and daratumumab are anticipated to extend relapse intervals and increase treatment accessibility.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy